<DOC>
	<DOCNO>NCT00354068</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving imatinib mesylate together temozolomide may kill tumor cell . PURPOSE : This phase I trial study side effect best dose imatinib mesylate give together temozolomide treat patient malignant glioma .</brief_summary>
	<brief_title>Imatinib Mesylate Temozolomide Treating Patients With Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity , attainable , imatinib mesylate combination temozolomide patient malignant glioma . - Characterize safety tolerability imatinib mesylate , include acute chronic toxicity , patient . - Determine effect temozolomide pharmacokinetics ( PK ) imatinib mesylate dose level . - Evaluate impact enzyme-inducing anti-epileptic drug ( EIAED ) coadministration PK imatinib mesylate use population-based PK approach . - Evaluate antitumor activity imatinib mesylate plus temozolomide . OUTLINE : This dose-escalation study imatinib mesylate . Patients stratify accord concurrent enzyme-inducing anticonvulsant ( e.g. , phenytoin , phenobarbital , carbamazepine , fosphenytoin , primidone , oxcarbazepine ) ( yes v ) . Patients receive oral imatinib mesylate twice daily day 1-8 oral temozolomide daily day 4-8 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts patient receive escalate dos imatinib mesylate maximum tolerate dose determine . On day 1 8 course 1 , blood drawn pharmacokinetic study . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma Any follow subtypes : Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic oligoastrocytoma Previous histologic diagnosis lower grade glioma allow histologic evidence progression diagnosis malignant glioma Multifocal disease allow Must undergone prior conventional externalbeam radiation therapy Stable disease , disease recurrence , relapsed disease Must receive systemic therapy recurrence relapse No prior progressive disease No central/systemic fluid collection ( pericardial effusion , pulmonary effusion , ascites ) ≥ grade 2 No evidence intratumor hemorrhage pretreatment diagnostic imaging , except stable postoperative grade 1 hemorrhage PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Absolute neutrophil count &gt; 1,500/mm³ Hemoglobin &gt; 9 g/dL Platelet count &gt; 100,000/mm³ AST ALT &lt; 2.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Creatinine &lt; 1.5 time ULN No chronic renal disease No active uncontrolled infection No uncontrolled diabetes No excessive risk bleeding , define occurrence follow : Stroke within past 6 month History CNS intraocular bleed Septic endocarditis No history labile hypertension No congestive heart failure No poorly control hypertension No myocardial infarction within past 6 month No history poor compliance antihypertensive regimen No severe and/or uncontrolled medical disease would preclude study participation No peripheral edema ≥ grade 2 No gastrointestinal bleeding No gross hematuria No active systemic bleeding Patients must experience toxicity ≥ grade 3 prior treatment either temozolomide imatinib mesylate No primary malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix cancer currently clinically significant require active intervention PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy Prior surgical resection ( ) allow At least 2 week since prior surgery At least 2 week since prior chemotherapy ( 6 week nitrosoureas ) At least 2 week since prior externalbeam radiotherapy At least 2 week since prior investigational drug More 1 week since prior biologic , immunotherapeutic , cytostatic agent No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>